CHIMERIX INC (CMRX)

US16934W1062 - Common Stock

1.01  +0.02 (+2.02%)

After market: 1.035 +0.02 (+2.48%)

News Image
7 days ago - Chimerix, Inc.

Chimerix Appoints Marc D. Kozin to Board of Directors

Veteran Industry Executive Brings More Than 35 Years of Corporate Strategy Experience

News Image
a month ago - Seeking Alpha

Chimerix files for $250M mixed shelf offering (NASDAQ:CMRX)

Chimerix files prospectus for $250M mixed shelf offering, however, it does not indicate an offer to sell.

News Image
a month ago - Chimerix, Inc.

Chimerix Reports Fourth Quarter and Year End 2023 Financial Results and Provides Operational Update

– ONC201 ACTION Study Progressing; Reiterate Interim OS Data Expected in 2025, Final OS Data Expected in 2026 – – Phase 2 ONC201 Data Published in...

News Image
a month ago - Chimerix, Inc.

Chimerix to Report Fourth Quarter and Year End 2023 Financial Results and Provide an Operational Update on February 29, 2024

DURHAM, N.C., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that...

News Image
3 months ago - Chimerix, Inc.

Chimerix Appoints Lisa Decker to Board of Directors

Seasoned Industry Executive Brings More Than 25 Years of Leadership and Business Development Experience

News Image
3 months ago - Chimerix, Inc.

Chimerix Appoints Lisa Decker to Board of Directors

Seasoned Industry Executive Brings More Than 25 Years of Leadership and Business Development Experience...

News Image
4 months ago - Seeking Alpha

Chimerix promotes Michelle Laspaluto to CFO (NASDAQ:CMRX)

Chimerix (CMRX) has promoted Michelle LaSpaluto, Vice President of Corporate Financial Planning and Investor Relations, to Chief Financial Officer effective Dec

News Image
4 months ago - Chimerix, Inc.

Chimerix Promotes Michelle LaSpaluto to Chief Financial Officer

Proven Leader Brings More Than 25 Years of Financial Experience

News Image
4 months ago - Chimerix, Inc.

Chimerix Promotes Michelle LaSpaluto to Chief Financial Officer

Proven Leader Brings More Than 25 Years of Financial Experience...

News Image
4 months ago - Chimerix, Inc.

Chimerix Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

DURHAM, N.C., Nov. 24, 2023 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), today announced that on November 20, 2023, the Compensation Committee of...

News Image
4 months ago - Seeking Alpha

Chimerix names Thomas Riga as Chief Operating and Commercial Officer (NASDAQ:CMRX)

Chimerix appoints Thomas Riga as Chief Operating and Commercial Officer, enhancing their executive leadership team.

News Image
4 months ago - Chimerix, Inc.

Chimerix Strengthens Executive Leadership Team with Appointment of Thomas Riga as Chief Operating and Commercial Officer

Seasoned Executive Brings More Than 25 Years of Industry Leadership Experience in Oncology Commercialization and Corporate Business Development

News Image
4 months ago - Chimerix, Inc.

Chimerix Strengthens Executive Leadership Team with Appointment of Thomas Riga as Chief Operating and Commercial Officer

Seasoned Executive Brings More Than 25 Years of Industry Leadership Experience in Oncology Commercialization and Corporate Business Development...

News Image
5 months ago - Chimerix, Inc.

Chimerix Reports Third Quarter 2023 Financial Results and Provides Operational Update

– Phase 3 ACTION Study Ongoing with 113 Sites Activated Across 12 Countries; Interim Survival and PFS Data on Track to Report in 2025 – – Actively...

News Image
5 months ago - Chimerix, Inc.

Chimerix to Report Third Quarter 2023 Financial Results and Provide an Operational Update on November 2, 2023

DURHAM, N.C., Oct. 26, 2023 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that...

News Image
7 months ago - Chimerix, Inc.

Chimerix Announces Data Highlighting Clinical Efficacy and Molecular Mechanisms of Response to ONC201 Treatment of H3 K27M-Mutant Diffuse Midline Gliomas Published in "Cancer Discovery"

Patients Treated with ONC201 Demonstrated Median Overall Survival (mOS) of 21.7 Months in the Front-Line Setting, Post Radiation, Versus 12 Months mOS...

News Image
8 months ago - InvestorPlace

CMRX Stock Warning! Smart Biotech Investors Will Avoid Chimerix Like the Plague.

CMRX stock may seem like a high-risk, high-potential play, but it makes sense why the market has bid down this biotech.

News Image
8 months ago - Chimerix, Inc.

Chimerix Reports Second Quarter 2023 Financial Results and Provides Operational Update

– Phase 3 ACTION Study Ongoing with 77 Sites Activated Across 11 Countries; Reiterate First Interim Overall Survival Analysis Expected Early 2025 – –...

News Image
8 months ago - InvestorPlace

7 Millionaire-Maker Penny Stocks to Buy Before the Window Closes

Although speculative trades are not for everyone, these millionaire-maker penny stocks could turn small bets into big returns.

News Image
8 months ago - Chimerix, Inc.

Chimerix to Report Second Quarter 2023 Financial Results and Provide an Operational Update on August 3, 2023

DURHAM, N.C., July 27, 2023 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that...

News Image
8 months ago - InvestorPlace

7 Small-Cap Stocks to Buy Before the Breakout

If you don’t mind the extreme risks involved, growth investors should target these ideas for best small cap stocks to buy.

News Image
9 months ago - InvestorPlace

Why These 7 Stocks Are the Best Ways to Play Biotech Right Now

With biotech stocks offering myriad viable opportunities irrespective of broader conditions, this sector is worth a closer look.

News Image
9 months ago - Seeking Alpha

Chimerix promotes CFO to CEO post (NASDAQ:CMRX)

Biopharmaceutical company Chimerix (CMRX) said on Tuesday that Chief Business Officer and CFO Mike Andriole has been promoted to the post of president and CEO.